Free Trial

OKYO Pharma (OKYO) Competitors

OKYO Pharma logo
$2.75 -0.01 (-0.36%)
Closing price 07/25/2025 03:58 PM Eastern
Extended Trading
$2.76 +0.00 (+0.18%)
As of 07/25/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OKYO vs. HUMA, ATXS, PRTA, RCKT, FHTX, GLUE, AURA, ALT, ABEO, and INBX

Should you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Humacyte (HUMA), Astria Therapeutics (ATXS), Prothena (PRTA), Rocket Pharmaceuticals (RCKT), Foghorn Therapeutics (FHTX), Monte Rosa Therapeutics (GLUE), Aura Biosciences (AURA), Altimmune (ALT), Abeona Therapeutics (ABEO), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry.

OKYO Pharma vs. Its Competitors

OKYO Pharma (NASDAQ:OKYO) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Company Net Margins Return on Equity Return on Assets
OKYO PharmaN/A N/A N/A
Humacyte N/A N/A -73.59%

In the previous week, Humacyte had 4 more articles in the media than OKYO Pharma. MarketBeat recorded 7 mentions for Humacyte and 3 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.40 beat Humacyte's score of 0.12 indicating that OKYO Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OKYO Pharma
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Humacyte
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

OKYO Pharma presently has a consensus target price of $7.00, suggesting a potential upside of 154.55%. Humacyte has a consensus target price of $11.71, suggesting a potential upside of 363.02%. Given Humacyte's higher probable upside, analysts clearly believe Humacyte is more favorable than OKYO Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OKYO Pharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Humacyte
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

OKYO Pharma has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

OKYO Pharma has higher earnings, but lower revenue than Humacyte.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OKYO PharmaN/AN/A-$4.71MN/AN/A
Humacyte$1.57M249.97-$148.70M-$0.69-3.67

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 5.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Humacyte beats OKYO Pharma on 7 of the 11 factors compared between the two stocks.

Get OKYO Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OKYO vs. The Competition

MetricOKYO PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$103.81M$3.05B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E RatioN/A21.1828.3320.08
Price / SalesN/A282.17430.8989.29
Price / CashN/A42.7636.2258.56
Price / Book-13.758.378.675.88
Net Income-$4.71M-$55.19M$3.25B$258.89M
7 Day Performance-8.03%5.86%4.23%3.71%
1 Month Performance13.64%17.29%10.50%11.72%
1 Year Performance102.06%4.39%34.42%18.00%

OKYO Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OKYO
OKYO Pharma
2.9241 of 5 stars
$2.75
-0.4%
$7.00
+154.5%
+103.7%$103.81MN/A0.007
HUMA
Humacyte
1.6488 of 5 stars
$2.31
+0.2%
$11.71
+408.2%
-69.0%$357.55M$1.57M-3.34150News Coverage
Analyst Forecast
ATXS
Astria Therapeutics
1.9099 of 5 stars
$6.27
+0.1%
$30.00
+378.9%
-44.4%$353.56MN/A-3.3530
PRTA
Prothena
3.7406 of 5 stars
$6.52
+3.6%
$31.50
+383.5%
-73.1%$351.30M$135.16M-3.14130Positive News
RCKT
Rocket Pharmaceuticals
4.8425 of 5 stars
$3.28
+4.6%
$18.60
+467.9%
-87.9%$349.72MN/A-1.25240Trending News
Analyst Forecast
Analyst Revision
Gap Down
FHTX
Foghorn Therapeutics
2.1319 of 5 stars
$6.27
+2.7%
$12.13
+93.5%
-5.1%$347.65M$22.60M-4.59120News Coverage
GLUE
Monte Rosa Therapeutics
2.0136 of 5 stars
$5.64
-3.3%
$15.33
+172.1%
+21.4%$346.61M$75.62M70.4590
AURA
Aura Biosciences
2.6553 of 5 stars
$6.82
+0.7%
$22.00
+222.8%
-29.6%$342.59MN/A-3.5950News Coverage
Positive News
ALT
Altimmune
2.1026 of 5 stars
$4.21
+3.8%
$18.20
+332.8%
-39.0%$341.07M$20K-3.3450
ABEO
Abeona Therapeutics
3.7549 of 5 stars
$6.57
-2.7%
$19.25
+193.2%
+29.8%$336.87MN/A-5.1990
INBX
Inhibrx Biosciences
3.1534 of 5 stars
$23.07
+4.3%
N/A+71.9%$333.98M$200K0.20166Positive News

Related Companies and Tools


This page (NASDAQ:OKYO) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners